2025
SJR Q2
JCR Q2 · 3,1
105 eşleşen makale
SCIE
Dergi ayrıntısı
Immunopharmacology and Immunotoxicology
- Yayıncı
- Taylor and Francis Ltd.
- Ülke
- United Kingdom · Western Europe
- Tür
- journal
- ISSN
-
0892397315322513
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,723
- Quartile Q2
- H-Index 67
- Atıf/yayın 2,85
- Doküman (3y) 277
- Atıf (3y) 846
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,1
- 5Y JIF 3,3
- JCI 0,81
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Immunology Q3
- Immunology and Allergy Q3
- Medicine (miscellaneous) Q2
- Pharmacology Q2
- Toxicology Q2
Alanlar
- Immunology and Microbiology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Immunology | Pharmacology & Pharmacy | Toxicology
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,723 | 3,1 | 3,3 | 0,81 | Q2 | 67 |
| 2024 | Q2 | Q2 | 0,725 | 3 | 3,1 | 0,8 | Q2 | 63 |
| 2023 | Q2 | Q2 | 0,68 | 2,9 | 3,2 | 0,71 | Q2 | 63 |
| 2022 | Q2 | Q2 | 0,594 | 3,3 | 3,1 | 0,68 | Q2 | 63 |
| 2021 | Q2 | Q2 | 0,631 | 3,7 | 3,6 | 0,68 | Q2 | 63 |
| 2020 | Q2 | Q3 | 0,701 | 2,7 | 2,9 | 0,7 | Q2 | 63 |
| 2019 | Q2 | Q3 | 0,635 | 2,4 | 2,1 | 0,66 | Q3 | 63 |
| 2018 | — | Q3 | — | 2,1 | 2 | 0,6 | Q3 | — |
| 2017 | Q2 | Q3 | 0,711 | 2 | 1,7 | 0,57 | Q3 | 63 |
| 2016 | Q2 | Q4 | 0,52 | 1,5 | 1,3 | — | — | 63 |
| 2015 | Q2 | Q3 | 0,522 | 1,6 | 1,3 | — | — | 63 |
| 2014 | Q2 | Q4 | 0,531 | 1,2 | 1,3 | — | — | 63 |
| 2013 | Q2 | Q4 | 0,417 | 1,1 | 1,2 | — | — | 63 |
| 2012 | Q2 | Q3 | 0,393 | 1,4 | 1,4 | — | — | 63 |
| 2011 | Q2 | Q3 | 0,461 | 1,8 | 1,4 | — | — | 63 |
| 2010 | Q2 | Q4 | 0,37 | 1,2 | 1,1 | — | — | 63 |
| 2009 | — | Q4 | — | 0,9 | 0,9 | — | — | — |
| 2008 | — | Q4 | — | 0,8 | 0,9 | — | — | — |
| 2007 | — | Q4 | — | 0,9 | 0,9 | — | — | — |
| 2006 | — | Q4 | — | 0,7 | — | — | — | — |
| 2005 | — | Q4 | — | 0,6 | — | — | — | — |
| 2004 | — | Q4 | — | 0,6 | — | — | — | — |
| 2003 | — | Q4 | — | 0,8 | — | — | — | — |
| 2002 | — | Q4 | — | 0,6 | — | — | — | — |
| 2001 | — | Q3 | — | 1,1 | — | — | — | — |
| 2000 | — | Q4 | — | 0,8 | — | — | — | — |
| 1999 | — | Q3 | — | 0,7 | — | — | — | — |
| 1998 | — | Q3 | — | 0,9 | — | — | — | — |
| 1997 | — | Q4 | — | 0,5 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q3 | Q2 | 108/183 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 163/356 |
| 2025 | TOXICOLOGY | SCIE | Q2 | Q2 | 52/106 |
| 2024 | IMMUNOLOGY | SCIE | Q3 | Q2 | 93/183 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 138/352 |
| 2024 | TOXICOLOGY | SCIE | Q2 | Q2 | 45/106 |
| 2023 | IMMUNOLOGY | SCIE | Q3 | Q2 | 108/181 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 147/354 |
| 2023 | TOXICOLOGY | SCIE | Q2 | Q2 | 49/106 |
| 2022 | IMMUNOLOGY | SCIE | Q3 | Q2 | 106/161 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 138/278 |
| 2022 | TOXICOLOGY | SCIE | Q2 | Q3 | 36/94 |
| 2021 | IMMUNOLOGY | SCIE | Q3 | Q2 | 109/162 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 132/279 |
| 2021 | TOXICOLOGY | SCIE | Q2 | Q3 | 39/94 |
| 2020 | IMMUNOLOGY | SCIE | Q4 | Q3 | 125/162 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 180/276 |
| 2020 | TOXICOLOGY | SCIE | Q3 | Q3 | 69/93 |
| 2019 | IMMUNOLOGY | SCIE | Q3 | Q3 | 118/159 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 167/271 |
| 2019 | TOXICOLOGY | SCIE | Q3 | Q3 | 59/92 |
| 2018 | IMMUNOLOGY | SCIE | Q4 | Q3 | 128/158 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 174/267 |
| 2018 | TOXICOLOGY | SCIE | Q3 | Q4 | 67/93 |
| 2017 | IMMUNOLOGY | SCIE | Q4 | Q3 | 125/155 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 170/261 |
| 2017 | TOXICOLOGY | SCIE | Q3 | Q4 | 59/94 |
| 2016 | IMMUNOLOGY | SCIE | Q4 | — | 131/151 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 201/257 |
| 2016 | TOXICOLOGY | SCIE | Q4 | — | 75/92 |
| 2015 | IMMUNOLOGY | SCIE | Q4 | — | 129/151 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 183/255 |
| 2015 | TOXICOLOGY | SCIE | Q4 | — | 69/90 |
| 2014 | IMMUNOLOGY | SCIE | Q4 | — | 133/148 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 205/255 |
| 2014 | TOXICOLOGY | SCIE | Q4 | — | 74/88 |
| 2013 | IMMUNOLOGY | SCIE | Q4 | — | 129/144 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 200/256 |
| 2013 | TOXICOLOGY | SCIE | Q4 | — | 72/87 |
| 2012 | IMMUNOLOGY | SCIE | Q4 | — | 118/137 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 185/261 |
| 2012 | TOXICOLOGY | SCIE | Q4 | — | 68/85 |
| 2011 | IMMUNOLOGY | SCIE | Q4 | — | 112/139 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 151/261 |
| 2011 | TOXICOLOGY | SCIE | Q3 | — | 57/83 |
| 2010 | IMMUNOLOGY | SCIE | Q4 | — | 116/134 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 191/252 |
| 2010 | TOXICOLOGY | SCIE | Q4 | — | 65/83 |
| 2009 | IMMUNOLOGY | SCIE | Q4 | — | 117/128 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 197/237 |
| 2009 | TOXICOLOGY | SCIE | Q4 | — | 69/77 |
| 2008 | IMMUNOLOGY | SCIE | Q4 | — | 115/121 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 188/219 |
| 2008 | TOXICOLOGY | SCIE | Q4 | — | 62/75 |
| 2007 | IMMUNOLOGY | SCIE | Q4 | — | 109/119 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 171/205 |
| 2007 | TOXICOLOGY | SCIE | Q4 | — | 61/73 |
| 2006 | IMMUNOLOGY | SCIE | Q4 | — | 110/117 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 181/199 |
| 2006 | TOXICOLOGY | SCIE | Q4 | — | 69/76 |
| 2005 | IMMUNOLOGY | SCIE | Q4 | — | 109/115 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 178/193 |
| 2005 | TOXICOLOGY | SCIE | Q4 | — | 67/75 |
| 2004 | IMMUNOLOGY | SCIE | Q4 | — | 100/111 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 162/187 |
| 2004 | TOXICOLOGY | SCIE | Q4 | — | 63/75 |
| 2003 | IMMUNOLOGY | SCIE | Q4 | — | 97/114 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 147/185 |
| 2003 | TOXICOLOGY | SCIE | Q4 | — | 60/77 |
| 2002 | IMMUNOLOGY | SCIE | Q4 | — | 105/119 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 153/188 |
| 2002 | TOXICOLOGY | SCIE | Q4 | — | 63/76 |
| 2001 | IMMUNOLOGY | SCIE | Q4 | — | 89/114 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 116/186 |
| 2001 | TOXICOLOGY | SCIE | Q3 | — | 47/78 |
| 2000 | IMMUNOLOGY | SCIE | Q4 | — | 96/116 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 141/181 |
| 2000 | TOXICOLOGY | SCIE | Q4 | — | 58/77 |
| 1999 | IMMUNOLOGY | SCIE | Q4 | — | 95/115 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 124/175 |
| 1999 | TOXICOLOGY | SCIE | Q3 | — | 50/74 |
| 1998 | IMMUNOLOGY | SCIE | Q4 | — | 93/120 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 103/178 |
| 1998 | TOXICOLOGY | SCIE | Q3 | — | 41/71 |
| 1997 | IMMUNOLOGY | SCIE | Q4 | — | 100/117 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 134/157 |
| 1997 | TOXICOLOGY | SCIE | Q4 | — | 52/63 |